Barinthus Biotherapeutics plc
Barinthus Biotherapeutics plc
Your view on BRNS
Overview
What the company does, where it operates, and who runs it.
About Barinthus Biotherapeutics plc
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- William J. Enright MBA
- Headquarters
- Zeus Building, Didcot, GB
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- William J. Enright MBA
- Headquarters
- Zeus Building, Didcot, GB
Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in developing novel T cell immunotherapeutics to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer.
It is advancing a pipeline of product candidates across a range of therapeutic areas, including VTP-300, an immunotherapeutic candidate designed as a potential component of a functional cure for chronic HBV infection; VTP-200, a non-surgical product candidate for persistent high-risk human papillomavirus (HPV); VTP-1000, an autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease; VTP-850, a second-generation immunotherapeutic candidate designed to treat recurrent prostate cancer; and VTP-1100, a preclinical cancer candidate designed to utilize the SNAP-CI platform to treat patients with HPV-related cancer.
The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Harwell, the United Kingdom.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Barinthus Biotherapeutics plc, and the rating behind it. BRNS last traded at $0.74; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Barinthus Biotherapeutics plc. Starting points for Barinthus Biotherapeutics plc: EPS -$1.02, beta -0.36 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Barinthus Biotherapeutics plc. Barinthus Biotherapeutics plc does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Barinthus Biotherapeutics plc. Trailing twelve-month EPS for Barinthus Biotherapeutics plc stands at -$1.02. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Barinthus Biotherapeutics plc. Barinthus Biotherapeutics plc has reported as a listed company since 2021. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Barinthus Biotherapeutics plc valued side by side against its closest peers. Barinthus Biotherapeutics plc is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Barinthus Biotherapeutics plc, and how their positions are changing. At a $30.2M market value, institutional positions materially move Barinthus Biotherapeutics plc's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Barinthus Biotherapeutics plc executives and directors. Shares of Barinthus Biotherapeutics plc have traded between $0.64 and $2.92 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Barinthus Biotherapeutics plc. Barinthus Biotherapeutics plc is a $30.2M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Barinthus Biotherapeutics plc. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Barinthus Biotherapeutics plc. Coverage tracks Barinthus Biotherapeutics plc within Biotechnology (Healthcare). Press releases and market coverage, newest first.